跳至主要内容
临床试验/NCT03600935
NCT03600935Unknown不适用

Safety and Feasibility of Early Discharge Using the Portico Self-Expanding Prosthesis for Transfemoral Transcatheter Aortic Valve Replacement: The SAFE TAVR Study

BC Centre for Improved Cardiovascular Health0 个研究点目标入组 315 人开始时间: 2018年10月最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
315
主要终点
The composite of all-cause mortality or stroke

研究概览

简要总结

The primary objective of this study is to determine the efficacy, safety and feasibility of next day discharge home in patients undergoing self-expandable transfemoral TAVR utilizing the Vancouver 3M Clinical Pathway.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with severe symptomatic aortic stenosis undergoing elective transfemoral TAVR with a self-expanding transcatheter heart valve
  • Considered at increased surgical risk by the Multidisciplinary Heart Team
  • Informed written consent

排除标准

  • Non-cardiovascular co-morbidity reducing life expectancy to <3 years
  • Any factor precluding 1 year follow-up
  • Inadequate CT image acquisition to perform area-based annular CT sizing, exclude adverse root features, and determine a coaxial valve deployment angle (CT is not required for valve-in-valve procedures)
  • Predicted inability to perform uncomplicated percutaneous vascular access and closure
  • Illiofemoral diameter <6 mm (for 23 and 25 mm valves) and <6.5 mm (for 27 and 29 mm valves) measured at or below the femoral head
  • Surgical prosthesis <23 mm (labelled size) for valve-in-valve procedure
  • In-patient (unless clinically stable, mobilizing at baseline, and primarily in hospital for logistical reasons)
  • Language barriers (inability to understand peri-procedural and discharge instructions)
  • Insufficient social support post procedure to allow next day discharge
  • Airway unfavourable for emergent intubation
  • Inability to lay supine without conscious sedation or general anaesthetic

研究组 & 干预措施

Vancouver Clinical Pathway

Experimental

The Vancouver Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.

干预措施: Vancouver Clinical Pathway (Other)

结局指标

主要结局

The composite of all-cause mortality or stroke

时间窗: 30 days post-procedure

The proportion of patients undergoing elective transfemoral TAVR using the Vancouver Clinical Pathway, who are discharged the next day

时间窗: Discharge 1 day after procedure

次要结局

  • Major/Life-threatening bleed(30 days post-procedure)
  • Any hospital readmission(30 days post-procedure)
  • >mild paravalvular regurgiation(Immediately after a procedure is performed or at time immediately prior to discharge, up to 48 hours after procedure)
  • All-cause mortality(30 days post-procedure)
  • Stroke(30 days post-procedure)
  • Major vascular complications(30 days post-procedure)
  • New permanent pacemaker(30 days post-procedure)
  • Patient is converted from local to general anaesthetic/receives intubation during procedure(This happens during the procedure)
  • Myocardial infarction(This happens during the procedure)
  • Repeat procedure for valve-related dysfunction(30 days post-procedure)
  • Stage 3 acute kidney injury (need for dialysis)(30 days post-procedure)
  • Patient-centred outcomes including health related quality of life as measured by KCCQ at baseline, 30 days and 1 year(Baseline, and 30 days and 1 year post-procedure)

研究者

申办方类型
Other
责任方
Sponsor

相似试验